基于英国生物银行对肾癌风险预测模型的外部验证与公共卫生建模
10个模型区分度合理(AUC>0.60),部分校准差;最佳模型在6年风险0.1-1.0%阈值下表现相似,优于年龄和性别筛查,但女性中表现较差。
要点
- 10个模型区分度合理(AUC>0.60),部分校准差。
- 最佳模型识别高危个体优于年龄和性别筛查,但获益相对较小。
- 所有模型在女性中表现均差于男性。
核心结论
- 最佳模型识别肾癌高危个体优于年龄和性别筛查,但获益相对较小。
- 所有模型在女性中表现均差于男性。
研究设计与样本
- 比较男性、女性和混合性别队列的区分度与校准度。
- 使用人群水平数据在6年风险0.1-1.0%阈值范围估计筛查场景下的模型表现。
主要发现
- 10个模型区分度合理(AUC>0.60),但部分模型校准差。
- 最佳模型在多个阈值下表现相似。
- 模型识别病例的能力优于年龄和性别筛查。
- 所有模型在女性中表现均差于男性。
关键数值与推荐
- 区分度合理定义为AUC>0.60。
- 筛查场景评估的6年风险阈值为0.1-1.0%。
临床怎么用
- 最佳模型可用于识别肾癌高危个体,但获益相对较小,需可行性研究确定是否适用于筛查项目。
局限性
- 模型在女性中表现较差。
- 部分模型校准差。
- 需可行性研究确定对筛查项目的适用性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To externally validate risk models for the detection of kidney cancer, as early detection of kidney cancer improves survival and stratifying the population using risk models could enable an individually tailored screening programme. METHODS: We validated the performance of 30 existing phenotypic models predicting the risk of kidney cancer in the UK Biobank cohort (n = 450 687). We compared the discrimination and calibration of models for men, women, and a mixed-sex cohort. Population level data were used to estimate model performance in a screening scenario for a range of risk thresholds (6-year risk: 0.1-1.0%). RESULTS: In all, 10 models had reasonable discrimination (area under the receiver-operating characteristic curve >0.60), although some had poor calibration. Modelling demonstrated similar performance of the best models over a range of thresholds. The models showed an improvement in ability to identify cases compared to age- and sex-based screening. All the models performed less well in women than men. CONCLUSIONS: The present study is the first comprehensive external validation of risk models for kidney cancer. The best-performing models are better at identifying individuals at high risk of kidney cancer than age and sex alone; however, the benefits are relatively small. Feasibility studies are required to determine applicability to a screening programme.
引用
- Harrison H, Pennells L, Wood A, et al. Validation and public health modelling of risk prediction models for kidney cancer using the UK Biobank. BJU Int. 2021. PMID: 34538014. doi:10.1111/bju.15598
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。